Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/32578| Title: | Testis cancer: Assessment and management. | Authors: | Frydenberg M. | Institution: | (Frydenberg) Department of Surgery, Monash University, Melbourne, Vic., Australia (Frydenberg) Centre of Urological Research, Monash Inst. of Repro./Development, Melbourne, Vic., Australia (Frydenberg) Department of Urology, Monash Medical Centre, Melbourne, Vic., Australia | Issue Date: | 18-Oct-2012 | Copyright year: | 2004 | Publisher: | Medicine Today Pty Ltd (P.O. Box 1473, Neutral Bay NSW 2089, Australia) | Place of publication: | Australia | Publication information: | Medicine Today. 5 (8) (pp 39-44), 2004. Date of Publication: August 2004. | Abstract: | * Patients with testis cancer usually present with a painless, hard, swollen mass in the testis. * Initial investigations comprise testicular ultrasonography and assessment of the tumour markers beta-human chorionic gonadotropin and alpha-fetoprotein. * Once testis cancer has been diagnosed patients should be referred to a urologist for staging investigations and surgical orchidectomy. * After orchidectomy, patients with stage 1 non-seminomatous tumours usually undergo surveillance, while those with stage 1 seminomas usually undergo adjuvant radiotherapy. * The use of cisplatin has revolutionised the treatment of metastatic testis cancer. * Survival rates for patients with early disease approach 100% and for those with advanced disease range from 70 to 95%. | ISSN: | 1443-430X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/32578 | Type: | Article |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.